Stockholders of Somerset-based health care company Catalent Inc. have approved its acquisition by Novo Holdings, parent of Novo Nordisk, it announced Wednesday.
The deal, which was first announced in February, is valued at $63.50 per share in cash, a value of approximately $11 billion — $16.5 billion including debt.
Novo has its North American headquarters in Plainsboro.
“Today’s outcome represents an important milestone towards the closing of this transaction, and we thank our stockholders for their overwhelming support and their confidence in the future of Catalent,” CEO and President Alessandro Maselli said in a prepared statement. “Following the closing of the transaction, we look forward to writing the next chapter for Catalent, benefiting from Novo Holdings’ expertise and resources as we continue to be a global leading independing (contract development and manufacturing organization), developing, manufacturing and supplying products that help people live better and healthier lives.”
The deal is expected to close by year-end, subject to customary conditions and approvals.
